期刊文献+

西格列汀联合胰岛素治疗2型糖尿病30例临床观察 被引量:8

下载PDF
导出
摘要 目的探讨磷酸西格列汀联合预混人胰岛素治疗2型糖尿病的临床疗效。方法将60例2型糖尿病随机分为治疗组和对照组,治疗组予西格列汀片100mg每天1片同时予诺和灵30R针早晚2次控制血糖;对照组予单用诺和灵30R针早晚两次控制血糖。观察两组治疗前后空腹及餐后2小时血糖、HbA1c、HOMA2-IR、HOMA2-%B、HOMA2-%S指数和低血糖发生率。结果治疗组与对照组治疗10周后两组的血糖、餐后2小时血糖以及HbA1c无显著性差异(P>0.05);治疗组胰岛素抵抗减轻,胰岛素敏感性和胰岛β细胞功能增强(均P<0.05);治疗期间治疗组低血糖发生率较对照组更低(P<0.05)。结论西格列汀联合胰岛素可以减轻胰岛素抵抗、增加胰岛β细胞的敏感性,并减少低血糖的风险。
作者 陈添 臧循雄
机构地区 乐清市人民医院
出处 《浙江实用医学》 2013年第2期102-103,共2页 Zhejiang Practical Medicine
  • 相关文献

参考文献5

  • 1Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in post- menopausal women with impaired glucose tolerance. Diabetes Care, 2000,23:650.
  • 2Vilsboll T, Rosenstock J, Yki - Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 dia- betes Diabetes. Diabetes, Obesity Metabolism, 2010,12:167.
  • 3Liliana Ferreira, Edite Teixeira - de - Lemos, Filipa Pinto, et al. Ef- fects of sitagliptin treatment on dysmetabolism, inflammation, and ox- idative stress in an animal model of type 2 diabetes (ZDF Rat)[EB/ OL]. Mediators Inflamm 2010,2010. 592760.
  • 4James M U, John Woods, Yun Ping Zhou, et al. Chronic inhibition of dipeptidyl peptidase- 4 with a Sitagliptin analog preserves Pancreatic - Cell Mass and Function in a Rodent Model of Type 2 Diabetes. Di- abetes,2006,55 : 1695.
  • 5张家庆.HOMA2-IR是个较好的胰岛素抵抗指数[J].中华内分泌代谢杂志,2005,21(4):304-305. 被引量:60

二级参考文献7

  • 1Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985,28:412-419.
  • 2Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care, 1998,21:2191-2192.
  • 3Turner RC, Levy JC, Rudesnki AS, et al. Measurement of insulin resistance and β-cell function: the HOMA and CIGMA approach. In: Belfiore F, et al (eds). Current topics in diabetes research, Front Diabetes (12). Basel, Karger, 1993,66-75.
  • 4Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004,27:1487-1495.
  • 5Matthews DR. Insulin resistance and β-cell function-a clinical perspective. Diabetes Obes Metab, 2001,3(Suppl 1):S28-S33.
  • 6Hermans MP, Levy JC, Morris RJ, et al. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia, 1999,42:678-687.
  • 7Hermans MP, Levy JC, Morris RJ, et al. Comparison of tests of β -cell function across a range of glucose tolerance from normal to diabetes. Diabetes, 1999,48:1770-1786.

共引文献59

同被引文献38

  • 1张家庆.HOMA2-IR是个较好的胰岛素抵抗指数[J].中华内分泌代谢杂志,2005,21(4):304-305. 被引量:60
  • 2Mu J,Woods J,Zhou YP,et al.Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserver pancreatic beta-cell mass and function in a rodent model of type 2 diabetes[J].Diabetes,2006,55:1695-1704.
  • 3James M U,John Woods,Yun Ping Zhou,et al.Chronic inhibition of dipeptidyl peptidase-4 with a Sitagliptin analog preserves Pancreaticβ-Cell Mass and Function in a Rodent Model of Type 2 Diabetes[J].Diabetes,2006,55:1695.
  • 4Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of beta-cell function: a meta analysis[J]. Am J Med Sci, 2009, 337(5): 321 -328.
  • 5Mu J, Petrov A, Eiermann GJ, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes[J]. Eur J Pharmacol,2009,623 (1-3): 148-154.
  • 6Aschner P,Katzerff HL,Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in pa- tients with type 2 diabetes[J]. Diabetes Obes Metab,2010,12 (3) :252-261.
  • 7Hallschmid M,Jauch-Chara K,Korn O,etal. Euglycemic infu- sion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects[J]. Diabe tes, 2010, 59(4): 1101-1107.
  • 8Adrian S,Dobs Barry J,Goldstein Pablo,et.al.Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebocontrolled 54-week trial in patients with type 2diabetes.[J].Journal of Diabetes,2013,5(1):68-79.
  • 9付鸿玉,唐海燕,金雪花.磷酸西格列汀治疗2型糖尿病40例临床观察[J].当代医学,2011,17(16):136-137. 被引量:21
  • 10孙静,蔡德海,宋光明,丁全福.治疗2型糖尿病新药物——西格列汀[J].武警医学,2011,22(11):997-1001. 被引量:12

引证文献8

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部